Semaglutide use before single-level lumbar fusion associated with fewer readmissions and 90-day costs.

Publication/Presentation Date

1-1-2025

Abstract

CONTEXT: Semaglutide, a glucagon-like protein-1 receptor agonist used in diabetes and obesity management, has demonstrated perioperative benefits in other surgical populations. However, its role in spine surgery remains unclear.

AIMS: This study aims to evaluate whether patients undergoing single-level lumbar fusion demonstrate: (1) fewer medical complications; (2) surgical complications; and (3) healthcare utilization as measured by readmissions and costs.

SETTINGS AND DESIGN: A retrospective cohort study using a national claims database from 2010 to 2021.

SUBJECTS AND METHODS: Patients with diabetes mellitus undergoing single-level lumbar fusion were identified and matched 1:5 using propensity scores based on age, sex, body mass index, smoking status, diabetes-related complications, insulin/metformin use, and Elixhauser Comorbidity Index (semaglutide:

STATISTICAL ANALYSIS USED: Multivariate logistic regression for binary outcomes; cost comparisons conducted with appropriate statistical adjustments.

RESULTS: No significant differences were observed in rates of cerebrovascular accidents, myocardial infarctions, venous thromboembolism, pneumonia, hypoglycemia, or surgical site infections (SSIs) (

CONCLUSIONS: Semaglutide use before single-level lumbar fusion is associated with reduced 90-day readmissions and costs without increasing complication risk.

Volume

16

Issue

4

First Page

401

Last Page

407

ISSN

0974-8237

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

41377827

Department(s)

Administration and Leadership

Document Type

Article

Share

COinS